07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor receptor superfamily member 11a (RANK; TNFRSF11A; CD265); receptor activator of NF-κB ligand (RANKL; TNFSF11); breast cancer

Cancer INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting RANKL could help treat BRCA1-mutant breast cancer. In tissue samples from breast cancer patients, levels of the RANKL receptor RANK were higher in tumors...
07:00 , Jul 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Receptor activator of NF-κB ligand (RANKL; TNFSF11); macrophage colony-stimulating factor 1 (CSF1; M-CSF)

Musculoskeletal disease INDICATION: Osteoporosis Cell culture and rodent studies suggest indazole-based inhibitors of RANKL signaling could help treat osteoporosis. Chemical synthesis and in vitro testing of indazole carboxylic acid analogs identified a compound that inhibited...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

Ablynx, Eddingpharm deal

Ablynx granted Eddingpharm exclusive rights in China, including Hong Kong and Macao, and Taiwan to develop and commercialize ozoralizumab ( ATN-103 ) for all indications. Ablynx will receive €2 million ($2.6 million) up front, payable...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Ablynx, Eddingpharm deal

Ablynx granted Eddingpharm exclusive rights in China and Taiwan to develop and commercialize ALX-0141 , which has completed a Phase I trial to treat bone loss-related disorders. Ablynx will receive €2 million ($2.7 million) up...
07:00 , Oct 21, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones...
00:29 , Oct 19, 2013 |  BC Extra  |  Company News

Eddingpharm gets Chinese rights to ALX-0141 from Ablynx

Ablynx N.V. (Euronext:ABLX) granted Eddingpharm Inc. (Shanghai, China) exclusive rights in China and Taiwan to develop and commercialize ALX-0141 , which has completed a Phase I trial to treat bone-loss related disorders. Ablynx will receive...
07:00 , Sep 1, 2011 |  BC Innovations  |  Cover Story

IL-20's osteoporosis connection

A group of Taiwanese researchers has shown that an antibody against IL-20 helped treat osteoporosis in mice. 1 The findings have grabbed the attention of Novo Nordisk A/S , which has an anti-IL-20 mAb in...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Clinical News

ALX-0141: Additional Phase I data

Additional data from a double-blind, placebo-controlled Phase I trial in 42 healthy postmenopausal women showed that 4 of 6 subjects receiving a single subcutaneous injection of 1 mg/kg ALX-0141 had significant suppression of C-terminal telopeptide...
07:00 , Oct 14, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Tumor necrosis factor receptor superfamily member 11a (TNFRSF11A; RANK; CD265); receptor activator of NF-kB ligand (RANKL; TNFSF11) Mouse studies...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Clinical News

ALX-0141: Phase I data

In an ongoing, double-blind, placebo-controlled Phase I trial in 42 healthy postmenopausal women, single subcutaneous injections of 0.003-1 mg/kg ALX-0141 were well tolerated with no serious adverse events or dose-limiting toxicities observed. Additionally, rapid reductions...